(Reuters) – The European Union’s drugs regulator on Thursday approved an increase in manufacturing capacity for the COVID-19 vaccine from Pfizer/BioNTech, which would help produce up to 50 million additional doses this year.
Both approved sites are located in Germany. One of them is operated by Sanofi-Aventis Deutschland Gmb and the other is operated by Siegfried Hameln GmbH, the European Medicines Agency said.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)
